Average Results by Medication at 18 Months

Not all GLP-1 medications produce the same outcomes. Here is a comparison based on clinical trial data at approximately 18 months (68 to 72 weeks):

• Semaglutide 2.4 mg (Wegovy): Average weight loss of 14.9% to 15.2% of body weight. For a 230-pound patient, roughly 34 to 35 pounds .
• Tirzepatide 15 mg (Mounjaro/Zepbound): Average weight loss of 20.9% of body weight. For a 250-pound patient, roughly 52 pounds .
• Liraglutide 3.0 mg (Saxenda): Average weight loss of 5% to 8% of body weight. For a 230-pound patient, roughly 12 to 18 pounds .
• Dulaglutide (Trulicity): Average weight loss of 3% to 5% of body weight. Primarily used for blood sugar control rather than weight loss .

The newer agents (semaglutide and tirzepatide) clearly outperform older GLP-1 options for weight management.

The 18-Month Trajectory

Regardless of which GLP-1 you take, the general weight loss trajectory follows a predictable pattern:

• Months 1 to 4: Titration and early loss. 5% to 8% of body weight lost. GI side effects are most common during this period. Appetite suppression develops progressively.
• Months 5 to 9: Peak weight loss rate. Patients on semaglutide typically lose 1 to 2 pounds per week; tirzepatide patients may lose 2 to 3 pounds per week. Metabolic markers improve notably.
• Months 10 to 14: Weight loss begins to decelerate. The body adapts to its new lower weight. Many patients notice a shift from rapid loss to gradual, steady progress.
• Months 15 to 18: Plateau and maintenance. Most patients have reached or are approaching their maximum response. The medication's role shifts from driving weight loss to preventing regain.

Health Benefits Beyond the Scale

At 18 months on GLP-1 therapy, the health improvements extend well beyond weight:

• Cardiovascular risk reduction: The SELECT trial demonstrated that semaglutide 2.4 mg reduced major cardiovascular events by 20% in patients with established heart disease . Similar cardiovascular trials for tirzepatide are underway.
• Blood sugar normalization: Many prediabetic patients return to normal glucose levels. Patients with type 2 diabetes often see A1C reductions of 1.5% to 2.5% .
• Improved lipid profiles: Triglycerides, LDL cholesterol, and overall lipid panels typically improve with significant weight loss.
• Reduced liver fat: Studies show 30% to 50% reductions in liver fat content with GLP-1 therapy, which is significant for patients with non-alcoholic fatty liver disease .
• Better sleep: Reduced sleep apnea severity and improved overall sleep quality are commonly reported.
• Mental health improvements: Many patients report reduced anxiety, improved self-image, and greater overall life satisfaction after significant weight loss.

Understanding the Plateau

Most GLP-1 patients experience a weight loss plateau somewhere between months 12 and 18. This is a normal physiological response, not a medication failure:

• Your resting metabolic rate decreases as you lose weight, reducing your daily caloric burn.
• Appetite-regulating hormones (leptin, ghrelin) recalibrate to your new weight.
• The caloric deficit that initially drove weight loss narrows as your smaller body requires less energy.

The GLP-1 medication continues to serve a critical function during this phase by preventing the weight regain that would otherwise occur due to these adaptive mechanisms .

What to Do at the 18-Month Check-In

• Get comprehensive lab work: A1C, fasting glucose, lipid panel, liver enzymes, kidney function, vitamin D, B12, and iron levels.
• Assess body composition: A DEXA scan reveals your lean-to-fat ratio and bone density, both important for long-term health planning.
• Review your medication: Discuss with your provider whether your current dose remains appropriate or if adjustments are warranted.
• Evaluate your exercise program: If you have not added resistance training, now is the time. Muscle preservation becomes increasingly important with extended weight loss.
• Address any lingering side effects: If GI issues persist at 18 months, your provider may suggest dose modification or supportive treatments.
• Set new goals: Whether those are fitness-related, lab-value targets, or quality-of-life improvements, having forward-looking goals keeps you motivated.

Frequently Asked Questions

Which GLP-1 produces the best results at 18 months?

Based on clinical trial data, tirzepatide (Mounjaro/Zepbound) produces the greatest average weight loss at 18 months, followed by semaglutide 2.4 mg (Wegovy). However, the "best" medication depends on your individual response, insurance coverage, tolerability, and health goals.

Is it safe to take GLP-1 medications for 18 months?

Yes. Clinical trials have studied GLP-1 medications for up to 2 years (and the SELECT trial followed semaglutide for up to 5 years). No significant new safety concerns have emerged with extended use . Regular physician follow-up remains important.

What happens if I stop my GLP-1 at 18 months?

Discontinuation studies consistently show that patients regain a significant portion of lost weight, typically 50% to 67% within one year of stopping treatment . This is why most providers recommend ongoing treatment or a carefully planned transition.

Can I switch GLP-1 medications at 18 months?

Switching is possible and sometimes beneficial. Patients who have plateaued on semaglutide, for example, may see additional weight loss after switching to tirzepatide. Your provider can guide the transition, including dose equivalency and titration adjustments.

Should I expect any new side effects at 18 months?

New side effects at 18 months are uncommon. Most patients who tolerate the medication through the first 6 months continue to tolerate it well. Any new symptoms should be reported to your provider for evaluation.

Plan Your Long-Term GLP-1 Strategy

Eighteen months of GLP-1 therapy is a major health investment, and the results speak for themselves. Whether you are maintaining, optimizing, or considering changes to your treatment plan, expert guidance makes the difference. FormBlends connects you with licensed providers who understand the full spectrum of GLP-1 therapy.

Schedule a consultation to review your progress and map out your next steps.